Clinical Trial Update: A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating single-agent lenalidomide in subjects with recurrent non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Celgene Corporation | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED